NexPoint Life Sciences DST
sponsored by NexPoint
NexPoint Life Sciences DST, sponsored by NexPoint, filed its first Form D with the SEC on Dec 28, 2021 for a $107.5 million offering. Its last Form D was filed Jun 6, 2022.
How it ended
Last Form D filed Jun 6, 2022.
Key facts
- Minimum investment
- $100,000From the Form D
- Offering size
- $107,550,012Equity offered, per the Form D
- Sold
- 97.5%Form D, Jun 6, 2022; the % is our arithmetic
- Investors reported
- Form D, Jun 6, 2022236
- Selling commissions
- Form D Item 15; the % is our arithmetic$9,303,076 · 8.6% of offering
- Financing
- Leveraged. This offering reports mortgage debt on the property.How it is financed ↓
- Offered under
- Rule 506(b)General advertising and solicitation are not permitted under this exemption.
Figures come from SEC Form D filings unless a source is cited. Sponsor-stated figures are as reported by the sponsor; Top1031 does not independently audit them. On a 45-day clock? Find day 45 and day 180 →
Using this record to judge the sponsor? A licensed 1031 specialist from our affiliated partner can talk it through with you.
Ask a 1031 specialist about this recordFree. About: NexPoint Life Sciences DST. Top1031 is not a broker-dealer.How was it financed, and what did it cost to sell?
Debt
- Financing
- Leveraged. This offering reports mortgage debt on the property.
Costs and terms from the Form D
- Selling commissions
- $9,303,076 · 8.6% of offering
- Finders’ fees
- $0
- Paid to officers, directors and promoters
- $3,245,300 · 3.0% of offeringForm D Item 16· The filing’s note: “Item 16 is an estimate of offering expenses and acquisition fees that may accrue to one or more Related Persons.”
- Broker-dealers named in the Form D
- 24 named in the Form D
Show the firms
- American Trust Investment Services, Inc. · CRD 3001
- Capulent LLC · CRD 155155
- Centaurus Financial, Inc. · CRD 30833
- Concorde Investment Services, LLC · CRD 151604
- Dempsey Lord Smith, LLC · CRD 141238
- Emerson Equity LLC · CRD 130032
- FNEX Capital, LLC · CRD 166316
- Great Point Capital LLC · CRD 114203
- Growth Capital Services, Inc. · CRD 124658
- Huntwicke Securities, LLC · CRD 146993
- Innovation Partners LLC · CRD 146344
- Kalos Capital, Inc. · CRD 44337
- Lightpath Capital, Inc. · CRD 34617
- Maxwell Financial Group, Inc. · CRD 167863
- McDermott Investment Services, LLC · CRD 154926
- Metropolitan Capital Investment Banc, Inc. · CRD 148820
- Network 1 Financial Securities Inc. · CRD 13577
- Patrick Capital Markets, LLC · CRD 16518
- Realized Financial, Inc. · CRD 22333
- Stax Capital · CRD 300607
- Stonecrest Capital Markets, Inc. · CRD 39616
- TCFG Wealth Management, LLC · CRD 164153
- Whitehall-Parker Securities, Inc. · CRD 10608
- Wilson-Davis & Co., Inc. · CRD 3777
Individual representatives named in Item 12 are not listed.
- Date of first sale
- Dec 16, 2021
- Minimum investment
- $100,000
Form D Item 15 and Item 16 amounts may be the issuer’s estimates; each percentage is Top1031’s arithmetic on two Form D figures. Item 16 can overlap Item 15, so Top1031 does not add them together. The issuer marked these amounts as an estimate.
Who's behind NexPoint Life Sciences DST?
- Sponsor
- Offerings on record
What does the SEC record show?
- Legal Trust name
- NexPoint Life Sciences DST
- SEC CIK
- 1901493
- First Form D
- Dec 28, 2021
- Latest Form D
- Jun 6, 2022
- Filings on record
- 14
- Offered under
- Rule 506(b)General advertising and solicitation are not permitted under this exemption.
- Source filing
SEC Form D filings, newest first
| Filed | Form | Offering amount | Amount sold | Investors | Filing on SEC EDGAR |
|---|---|---|---|---|---|
| Form D/A | $107,550,012 | $104,959,651+$498,815 | 236+2 | EDGAR | |
| Form D/A | $107,550,012 | $104,460,836+$150,000 | 234+1 | EDGAR | |
| Form D/A | $107,550,012 | $104,310,836+$2,120,727 | 233+6 | EDGAR | |
| Form D/A | $107,550,012 | $102,190,109+$4,352,569 | 227+9 | EDGAR | |
| Form D/A | $107,550,012 | $97,837,540+$8,843,906 | 218+22 | EDGAR | |
| Form D/A | $107,550,012 | $88,993,634+$7,183,290 | 196+21 | EDGAR | |
| Form D/A | $107,550,012 | $81,810,344+$13,878,126 | 175+30 | EDGAR | |
| Form D/A | $107,550,012 | $67,932,218+$28,035,962 | 145+25 | EDGAR | |
| Form D/A | $107,550,012 | $39,896,256+$4,895,136 | 120+20 | EDGAR | |
| Form D/A | $107,550,012 | $35,001,120+$10,765,926 | 100+30 | EDGAR | |
| Form D/A | $107,550,012 | $24,235,194+$11,478,154 | 70+34 | EDGAR | |
| Form D/A | $107,550,012 | $12,757,040+$7,487,388 | 36+28 | EDGAR | |
| Form D/A | $107,550,012 | $5,269,652+$70,000 | 8+1 | EDGAR | |
| Form D | $107,550,012 | $5,199,652 | 7 | EDGAR |
Show all 14 SEC Form D filings
Amounts, investor counts and minimums are as filed with the SEC on Form D. The change lines are Top1031’s arithmetic between consecutive filings; a new Form D notice starts a new count.
A Form D is the notice a sponsor files when it starts raising money. A Form D filing does not mean the SEC approved, endorsed, or verified the offering.
Common questions
- What happened to NexPoint Life Sciences DST?
- NexPoint Life Sciences DST is a Historical offering. Last Form D filed Jun 6, 2022.
DST interests are illiquid private securities. You may lose some or all of your investment. Distributions, tax treatment, and exit timing are not guaranteed. Review the current offering documents before investing.